Core Insights - Sichuan Maikelong Biotechnology Co., Ltd. has completed a multi-million Pre-A+ round financing, led by Boyuan Capital, aimed at accelerating technology development and clinical project advancement [1][9] - This financing marks another significant funding achievement for Maikelong within a year, reinforcing its industrialization path in microfluidic technology [1][9] Company Overview - Maikelong is a technology transfer enterprise originating from the Membrane Science and Functional Materials Research Room at Sichuan University, with core competencies built on nearly 20 years of technological accumulation [3] - The company focuses on drug delivery and medical device sectors, leveraging advanced micro-sphere material pilot platforms to extend the application of microfluidic manufacturing technology [9] Technological Advancements - The team has established cutting-edge theories for preparing functional microspheres using microfluidic technology, innovating fluid operation strategies in confined spaces and developing new methods for chip design [5][7] - Maikelong has successfully created a batch production system for microspheres, achieving controlled preparation of hundreds of functional microspheres, thus overcoming critical technological bottlenecks in high-precision microsphere production in China [7] Applications and Market Potential - Microfluidic technology enables precise control of liquid flow at micro and nano scales, facilitating the production of uniform-sized, adjustable-structure, and customized functional microspheres [7] - The applications of microspheres are extensive, particularly in drug delivery, where they can target disease sites accurately, reducing side effects, and in medical devices, where they serve as core materials for diagnostic reagents, enhancing diagnostic accuracy [7][9] Future Plans - Following this round of financing, Maikelong plans to increase R&D investment, expedite clinical validation processes, and optimize market entry strategies [9] - The company aims to promote the industry-wide adoption of microfluidic manufacturing technology, opening new chapters in the development of the microfluidic sector [9] Industry Context - Chengdu High-tech Zone will continue to focus on cutting-edge biomedicine, enhancing the service ecosystem throughout the entire lifecycle and chain to help more companies overcome critical technological challenges [10]